{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:53:29Z","timestamp":1787500409583,"version":"build-2736575974"},"reference-count":28,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"abstract":"<jats:p>Type III hyperlipoproteinemia (type III HLP) rarely manifests in childhood. Long-term follow-up (37 years) of the first patient revealed hypothyroidism at diagnosis requiring thyroxine replacement, palmar xanthomas requiring surgical removal, splenomegaly requiring splenectomy, 18 episodes of pancreatitis and premature coronary artery disease. Investigation revealed an apolipoprotein E phenotype of E2\/E2 and partial lipoprotein lipase deficiency. Investigation of the second patient revealed a combination of apoE2\/E2 phenotype and heterozygous familial hypercholesterolaemia. The third patient had a complete deficiency of lipoprotein lipase activity, an abnormal thyroid stimulating hormone on diagnosis (with subsequent normalisation without treatment), and apoE2\/E2 phenotype. Type III HLP is a serious disorder with lifelong consequences of premature vascular disease and recurrent pancreatitis. Early presentation of disease in our patients was associated with additional precipitating factors. Drug treatment of paediatric type III HLP is indicated if dietary modifications alone are insufficient in managing the dyslipidaemia.<\/jats:p>","DOI":"10.1136\/bcr.02.2011.3895","type":"journal-article","created":{"date-parts":[[2011,6,9]],"date-time":"2011-06-09T17:47:57Z","timestamp":1307641677000},"page":"bcr0220113895","source":"Crossref","is-referenced-by-count":11,"title":["Case series of type III hyperlipoproteinemia in children"],"prefix":"10.1136","volume":"2011","author":[{"given":"Michelle","family":"Fung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Frohlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2011,6,9]]},"reference":[{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.1","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/S0022-2275(20)32417-2","article-title":"Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes.","volume":"40","author":"Mahley","year":"1999","journal-title":"J Lipid Res"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-120-12-199406150-00009"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0140-6736(72)90611-3","article-title":"Type-3 hyperlipoproteinaemia in a child.","volume":"1","author":"Godolphin","year":"1972","journal-title":"Lancet"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.4","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1161\/01.ATV.15.10.1704","article-title":"Mutations in the gene for lipoprotein lipase. A cause for low HDL cholesterol levels in individuals heterozygous for familial hypercholesterolemia.","volume":"15","author":"Pimstone","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.5","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M300295-JLR200"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1997.1390964.x"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(88)80536-5"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.1991.tb00428.x","article-title":"Expression of type III hyperlipoproteinaemia in a subject with secondary hypothyroidism bearing the apolipoprotein E2\/2 phenotype.","volume":"230","author":"Feussner","year":"1991","journal-title":"J Intern Med"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2000.tb00429.x"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.10","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.76.901.712"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.11","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/pgmj.75.888.633","article-title":"Unusual presentations to a lipid clinic.","volume":"75","author":"Crook","year":"1999","journal-title":"Postgrad Med J"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15594-3"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0025-7125(16)30179-1","article-title":"Secondary causes of hyperlipidemia.","volume":"78","author":"Stone","year":"1994","journal-title":"Med Clin North Am"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(99)00212-9"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.15","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8628(19961016)65:2<149::AID-AJMG14>3.0.CO;2-Q"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/0026-0495(95)90052-7","article-title":"Coexisting type III hyperlipoproteinemia and familial hypercholesterolemia: a case report.","volume":"44","author":"Sakuma","year":"1995","journal-title":"Metab Clin Exp"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.17","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.ATV.11.5.1137","article-title":"Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction.","volume":"11","author":"Hopkins","year":"1991","journal-title":"Arterioscler Thromb"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.18","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/S0140-6736(01)07205-1","article-title":"Follow-up of type III hyperlipoproteinaemia in a child.","volume":"358","author":"Fung","year":"2001","journal-title":"Lancet"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(99)00015-5"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.20","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0022-2275(20)33444-1","article-title":"Effect of labeling of plasma lipoproteins with [(3)H]cholesterol on values of esterification rate of cholesterol in apolipoprotein B-depleted plasma.","volume":"41","author":"Dobi\u00e1sov\u00e1","year":"2000","journal-title":"J Lipid Res"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.21","first-page":"65","article-title":"Measurement of fractional esterification rate of cholesterol in plasma depleted of apoprotein B containing lipoprotein: methods and normal values.","volume":"45","author":"Dobi\u00e1sov\u00e1","year":"1996","journal-title":"Physiol Res"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF02803766","article-title":"Role of hypertriglyceridemia in the pathogenesis of experimental acute pancreatitis in rats.","volume":"20","author":"Kimura","year":"1996","journal-title":"Int J Pancreatol"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.23","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0889-8553(21)00513-6","article-title":"Hyperlipidemic pancreatitis.","volume":"19","author":"Toskes","year":"1990","journal-title":"Gastroenterol Clin North Am"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00431-003-1181-3","article-title":"The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation.","volume":"162","author":"Dirisamer","year":"2003","journal-title":"Eur J Pediatr"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02593-7"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.26","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000035247.42888.82"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(01)00584-6"},{"key":"2025082800475790000_2011.jun09_1.bcr0220113895.28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1542\/peds.97.5.619","article-title":"Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group.","volume":"97","author":"Lambert","year":"1996","journal-title":"Pediatrics"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr.02.2011.3895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:48:03Z","timestamp":1756367283000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr.02.2011.3895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,9]]},"references-count":28,"alternative-id":["10.1136\/bcr.02.2011.3895"],"URL":"https:\/\/doi.org\/10.1136\/bcr.02.2011.3895","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,9]]}}}